The current success of HER2 and MET targeted therapies in advanced and/or metastatic malignancies, and the recent success of trastuzumab and crizotinib demonstrating a positive response in a HER2 and MET-mutant CUP tumour, provides evidence for future evaluation of these genes as druggable targets in patients with CUP. The gene discussed is MET; the disease is neoplasm.